Hit & Lead Finding
Prioritize promising candidates with a broader view of target interactions.
AI-DRIVEN DRUG DISCOVERY
Accelerating drug discovery through the Molecular Fingerprint™ Platform.
IBIS Therapeutics uses an AI-driven, proteome-wide approach to help identify promising drug candidates, assess selectivity and safety, deconvolute phenotypic targets, and predict polypharmacology.
Proteome-Wide Molecular Fingerprint™
Evaluating interactions across diverse drug candidates and a curated collection of disease-modifying and toxicity-causing protein targets.
Novel Drug Discovery
Selectivity & Safety Assessment
Phenotypic Target Deconvolution
Polypharmacology Prediction
THE CHALLENGE
A narrowed view can miss efficacy—and expose unwanted toxicity.
The current public IBIS site frames the problem around understanding drug-candidate interactions beyond a single target. Its Molecular Fingerprint™ Platform is positioned to broaden that view.
Lead Optimization
Explore selectivity, safety, mutations and binding effects as candidates evolve.
Preclinical to Human Trials
Support discovery decisions through the stages of drug development.
ENGAGEMENT
From platform capabilities to collaborative discovery.
IBIS currently presents three engagement pathways: collaborative research, partnered discovery, and discovery services.
Discuss a CollaborationCollaborative Research
Investigate Ibis safety profiling across projects and therapeutic areas and generate machine-learning models for toxicity profiling.
Partnered Discovery
Explore opportunities around target-disease combinations, repurposing, and preclinical assets.
Discovery Services
Prioritize compounds, explore mutation effects on binding, and deconvolute targets from phenotypic assays.